AUA: HIFU Demand Remains Healthy; HIFI-2 Supportive of Biz Momentum

Research evidence excerpt

AUA: HIFU Demand Remains Healthy; HIFI-2 Supportive of Biz Momentum

USA | Medical Supplies & Devices

EDAP TMS EquityMayResearch17, 2026

COMPANY UPDATEAUA: HIFU Demand Remains Healthy; HIFI-2

RATING HOLDSupportive of Biz Momentum

PRICE $4.17^

We caught up with EDAP management at the AUA conference. Overall, we

characterize management's tone as optimistic about ongoing momentum and PRICE TARGET | % TO PT $4.50 | +8%

52W HIGH-LOW $5.05 - $1.21

demand for Focal One HIFU. Foot traffic at the booth also seemed healthy. We

FLOAT (%) | ADV MM (USD) 99.9% | 0.14

expect the next catalyst for EDAP will be the company's June 1 investor day

MARKET CAP $156.2M

where we expect mgmt to provide an update on its growth strategy, indication

TICKER EDAP

expansion oppy, and provide LRP growth targets. ^Prior trading day's closing price unless otherwise

noted.

At the AUA conference, we caught up with EDAP management including Ryan Rhodes, CEO,

and Ken Mobeck, CFO. Overall, we characterize management's tone as optimistic about ongoing

Cal CHANGE TO JEFe JEF vs CONS

momentum and demand for Focal One HIFU. Foot traffic at the booth also seemed healthy. We

2026 2027 2026 2027

expect the next catalyst for EDAP will be the company's June 1 investor day where we expect

REV NA NA +5% -9%

mgmt to provide an update on its growth strategy, indication expansion oppy, and provide LRP

growth targets. EPS NA NA -52% -49%

EDAP has made good progress in building out the visualization capabilities of its Focal One 2026 ($) Q1A Q2 Q3 Q4 Cal

platform. With its Focal One i system EDAp expanded its HiFUsion compatibility to include PSMA EPS (0.24) (0.28) (0.25) (0.27) (1.04)

PET scans, ExactVu Micro-Ultrasound, Unfold AI, and OnQ Prostate. EDAP also incorporates Koelis PREV